gene therapy trial can continue targeted genetics corp said the food and drug administration removed the hold on its phase i ii clinical trial of a gene therapy treatment that was paused after a year old arthritis patient died this summer the seattle biotechnology company said the fda reviewed safety data from all subjects in the trial and determined the drug tgacc didnt contribute to the patients death the company said it will revise the phase i ii trials informed consent to include information about fatal serious adverse events and will amend the protocol as suggested by the fda 
